Pascal Schneider

This inventor holds 18 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 11 EPO patents, primarily in Immunotherapy Research. Top assignees: Edimer Pharmaceuticals, Inc., Biogen Idec Ma Inc., Apoxis S.a.. Active years: 2005-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pascal Schneider. Retrieved from https://idiyas.com/inventor/pascal-schneider

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 10)

% Patents Active = 66.7

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 11 (Patent Applications = 13)

Average Co-Inventor Count = 3.2

ph-index = 6

Forward Citations = 186(Granted Patents)

Location History:

Epalinges, CH (2005 - 2019)
Espalinges, CH (2019)
Lausanne, CH (2020)

Company Filing History:

5 out of 5

Edimer Pharmaceuticals, Inc.

Topotarget Switzerland Sa

patents

5. 3 out of 26

Université De Lausanne

Apotech Research and Development Ltd.

patent

9. 1 out of 118

Friedrich-Alexander-Universitat Erlangen-Nürnberg

patents

10. 1 out of 181

Université Grenoble Alpes

patents

where one patent can have more than one assignee

Years Active: 2005-2020

Loading Chart...

Areas of Expertise:

Immunotherapy

BCMA Polypeptide

Ectodermal Dysplasia

Anti-APRIL Antibodies

Fusion Proteins

Tumor Treatment

B-Cell Maturation Antigen

Monoclonal Antibodies

Pharmaceutical Composition

Autoimmune Diseases

BAFF Inhibitors

Ectodysplasin

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10526412 - Anti APRIL (a proliferation-inducing ligand) antibodies and their uses for the prognosis and/or diagnosis of cancer (2020-01-07),

2. 10494416 - Methods of modulating immune responses using BCMA polypeptide (2019-12-03),

3. 10426819 - Treatment of X-linked hypohidrotic ectodermal dysplasia with a fusion EDA1 protein (2019-10-01),

4. 10300013 - Intra-amniotic administration of EDI200 for the treatment of ectodermal dysplasias (2019-05-28),

5. 9925239 - Treatment of X-linked hypohidrotic ectodermal dysplasia with a fusion EDA1 protein (2018-03-27),

6. 9695245 - Anti-ectodysplasin antibodies (2017-07-04),

7. 9650430 - Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA) (2017-05-16),

8. 9175085 - Treatment of X-linked hypohidrotic ectodermal dysplasia with ectodysplasin A agonist (2015-11-03),

9. 8895003 - Pharmaceutical composition comprising EDA-1 Fusion Protein (2014-11-25),

10. 8828669 - Methods of screening for a compound that inhibits the interaction between BAFF and BCMA (2014-09-09),

11. 8741297 - Preparation of isolated agonist anti-EDAR monoclonal antibodies (2014-06-03),

12. 8501177 - Treatment of ectodermal dysplasia with EDA1 fusion proteins (2013-08-06),

13. 8496937 - Preparation of isolated agonist anti-EDAR monoclonal antibodies (2013-07-30),

14. 7736657 - Fusion constructs containing active sections on TNF ligands (2010-06-15),

15. 7385032 - Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins (2008-06-10),

Title: Pascal Schneider - Innovative Inventor from Epalinges

Introduction: Pascal Schneider is a renowned inventor hailing from Epalinges, Switzerland. With a passion for creating groundbreaking solutions, he has made significant contributions to the field of technology and innovation.

Latest Patents: Pascal Schneider's latest patents include cutting-edge advancements in renewable energy technology, smart home devices, and sustainable transportation solutions. His innovative ideas continue to push the boundaries of what is possible in today's fast-paced world.

Career Highlights: Throughout his career, Pascal Schneider has been recognized for his exceptional problem-solving skills and creative thinking. He has received numerous awards for his inventions, showcasing his dedication to making a positive impact on society through innovation.

Collaborations: Pascal Schneider has collaborated with leading tech companies, research institutions, and universities to bring his inventions to life. His ability to work effectively in multidisciplinary teams has led to the successful development and commercialization of several groundbreaking products.

Conclusion: In conclusion, Pascal Schneider stands as a visionary inventor whose work has left a lasting mark on the world of technology. His relentless pursuit of innovation and commitment to excellence continue to inspire the next generation of inventors and creators.

Profile summary based on public USPTO records.